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7INTRODUCTION
Gastrointestinal bleeding encompasses a broad array of clinical
scenarios. The spectrum is diverse because of the multiple types of
lesions that can cause bleeding, and because bleeding can occur from
virtually anywhere in the gastrointestinal tract.
Additionally, gastrointestinal bleeding varies greatly in its volume
and as such may be massive or trivial, and may be clinically apparent or
altogether hidden.
Gastrointestinal bleeding is manifest in one or more of the
following clinical scenarios: (1) bleeding is from the upper
gastrointestinal tract; (2) bleeding is from the lower gastrointestinal tract;
(3) bleeding is occult (ie, unknown to the patient); or (4) bleeding is
clinically obvious but the site (ie, whether it is from the upper or lower
gastrointestinal tract) is obscure.
Patients with occult bleeding are challenging because the patient is
unaware of the bleeding and clinical clues to its cause are typically
lacking. Patients with obscure bleeding are particularly challenging
because their bleeding is typically recurrent and the site of bleeding is
difficult accurately to identify.
8Gastrointestinal bleeding results in over 300,000 hospitalizations
annually. Bleeding from the upper gastrointestinal tract is approximately
five times more common than from the lower gastrointestinal tract and
seems to be more common in men and the elderly.
Despite a number of recent advances in the management of patients
with gastrointestinal bleeding, several fundamental clinical principles
remain constant, the most important of which is immediate assessment
and stabilization of the patient’s hemodynamic status.
9Aims & Objectives
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AIM OF THE STUDY
1. To find out the prevalence of nature of lesion by Upper Gastro
Endoscopy in patients admitted with UGI bleed
2. To find out the prevalence of nature of lesion in patients with mild,
moderate and major bleed
3. To identify the risk factors associated with poor outcome
4. To assess the nature of lesions in patients with UGI bleed
presenting with co-morbidities
5. To find out the nature of lesions in patients with UGI bleed and
correlate with their clinical presentation
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REVIEW OF LITERATURE
Gastrointestinal bleeding is one of the common gastroenterological
emergencies. The spectrum is diverse because of the multiple types of
lesions that can cause bleeding, and because bleeding can occur from
virtually anywhere in the gastrointestinal tract1. Bleeding from the upper
gastrointestinal tract is approximately five times more common than from
the lower gastrointestinal tract and seems to be more common in men and
the elderly2,3. Despite a number of recent advances in the management of
patients with gastrointestinal bleeding, several fundamental clinical
principles remain constant, the most important of which is immediate
assessment and stabilization of the patient’s hemodynamic status.
Thereafter, a careful history and physical examination follows, and with it
the etiology and source of bleeding predicted. Specific investigation then
follows and further delineates the source of bleeding.
Once the bleeding site is identified, it must be stopped and treated.
Subsequently, recurrent bleeding should be prevented.
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CLINICAL PRESENTATION
The clinical presentation of patients with gastrointestinal bleeding
typically reflects the site, etiology, and rate of bleeding. Gastrointestinal
tract bleeding may manifest in one or more ways.
Hematemesis and melena are the most common manifestations of
upper gastrointestinal bleeding. Hematemesis is defined as vomiting of
blood and is caused by upper gastrointestinal bleeding from the
esophagus, stomach, or proximal small bowel. Blood may be bright red or
it may be old and take on the appearance of coffee grounds. Melena is
defined as passage of black, tarry, and foul-smelling stools. The black,
tarry character of melena is caused by degradation of blood in the more
proximal colon.
INITIAL PATIENT ASSESSMENT
When a patient is found to have one of the previously mentioned
manifestations of gastrointestinal bleeding, the first step in management
should be to assess the severity of bleeding. Assessment of the patient’s
hemodynamics should be emphasized. Ongoing assessment of the vital
signs further focuses resuscitation efforts, and also provides important
prognostic information.
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Table 1:
Hemodynamics, vital signs and blood loss
Hemodynamics vital sign % Blood loss (fraction ofintravascular volume) Bleed type
Shock (resting hypotension) 20-25 Massive
Postural (orthostoatic tachycardia or
hypotension)
10-20 Moderate
Normal < 10 Minor
RESUSCITATION4
The more severe the bleeding, the more vigorous the resuscitation efforts
should be. In patients who have any evidence of haemodynamic
instability, two large - bore intravenous catheters should be placed
immediately. Crystalloid (normal saline or lactated Ringer’s solution)
should be infused as rapidly as the patient’s cardiovascular system allows
to restore the vital signs toward normal. ICU monitoring is indicated in
hemodynamically unstable patients. Supplemental oxygen by nasal
cannula or facemask should be given liberally. Vital signs and urine
output should be monitored closely, and in selected situations (for patients
with underlying cardiopulmonary disease) central venous monitoring is
helpful. The importance of aggressive ICU monitoring and resuscitation
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has been emphasized by investigation suggesting that it may decrease
mortality1.
In addition, patients must typically undergo blood transfusion as
needed. If the patient has subnormal tissue oxygenation, transfusion
should be aggressive. Patients with continued instability in vital signs,
continued bleeding, symptoms of poor tissue oxygenation, or persistently
low hematocrit values (20%–25%) likewise should probably be
transfused continuously. It is most appropriate to raise the hematocrit to a
level of 30% in elderly patients, whereas in younger, otherwise healthy
patients, hematocrit values in the 20% to 25% range may be satisfactory;
in those with portal hypertension, it should not be above 27% to
28%. Transfusion should be with packed red blood cells, except in rare
circumstances where whole blood transfusions may be used. Serial
hematocrits are not a substitute, for ongoing clinical assessment of the
hemodynamics.
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HISTORY, SYMPTOMS, AND SIGNS
Historical features important in assessing the etiology of gastrointestinal
bleeding are shown below
 Age
 Prior bleeding
 Previous gastrointestinal disease
 Previous surgery
 Underlying medical disorder (especially liver disease)
 Nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin (ASA)
 Abdominal pain
 Change in bowel habits
 Weight loss or anorexia
 History of oropharyngeal disease
Symptoms
Hematamesis and Melena
Postural giddiness
Palpitation
Sweating
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Signs
BP: Resting hypotension and postural hypotension and tachycardia
Signs of liver disease: Jaundice, spider angiomata, palmar erythema,
dupuytren’s contracture.
Acanthosis nigricans (underlying malignancy)
Abdominal mass and tenderness
LABORATORY EVALUATION5
During initial evaluation the following tests are of urgent importance.
Hemoglobin
Hematocrit
Blood urea nitrogen5
Serum creatinine5
CLINICAL LOCALIZATION OF BLEEDING
The localization of bleeding should begin with the history and
physical examination and should be focused immediately, during
hemodynamic stabilization. Hematemesis denotes an upper
gastrointestinal source of bleeding. Melena indicates that blood has been
in the gastrointestinal tract for extended periods of time and is usually the
result of upper gastrointestinal bleeding, but its source may be the distal
small bowel or even the ascending colon. In the latter instance, the
volume of bleeding is too little to cause hematochezia6 but sufficiently
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large to provide hemoglobin for degradation. The nasogastric lavage has
been commonly used to help differentiate upper from lower
gastrointestinal bleeding7.8 A bloody aspirate indicates that the upper
gastrointestinal tract is the source of bleeding, because the false-positive
rate is extremely low, and is usually caused by nasogastric trauma8.
Assessment of vital signs and the use of bedside diagnostic criteria
as previously mentioned is a more effective means to determine the
activity of bleeding. If there is any question about the location of bleeding
in a patient with hematochezia6, especially in patients with hemodynamic
instability, a nasogastric tube should be placed. Other clues that can help
localize an upper gastrointestinal source of bleeding include hyperactive
bowel sounds and an elevation in the blood urea nitrogen level out of
proportion to creatinine.
DIAGNOSIS AND THERAPY
Diagnostic tests play a central role in the evaluation of patients
with gastrointestinal bleeding. The major categories of tests available
include the following: (1) endoscopy; (2) barium radiographs; (3)
radionuclide imaging; (4) angiography; and (5) miscellaneous tests (ie,
abdominal CT scanning). The radiographic tests allow diagnosis only,
whereas endoscopic tests allow both diagnosis and therapy. The
importance of endoscopic therapy is emphasized by studies performed
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before the advent of endoscopic therapy, which demonstrated that
endoscopy per se did not affect outcome for patients with upper
gastrointestinal bleeding9.
A major goal of treatment is to stop active bleeding and prevent
recurrent bleeding. The major forms of therapy include (1)
pharmacologic, (2) endoscopic, (3) angiographic, and (4) surgical. The
use of each of these modalities has undergone tremendous change over
the past two decades. Traditionally, UGIB is categorized as being either
variceal or non variceal for planning appropriate therapeutic strategy.
NON VARICEAL BLEED
EPIDEMIOLOGY
Several population-based and prospective studies support peptic
ulcer disease (PUD) being the most common cause of acute UGIB10. PUD
traditionally refers to either gastric or duodenal ulcers, but under a broad
heading of ‘‘ulcers’’ some investigators also include esophageal ulcers11
Approximately 50% of all cases of acute UGIB are attributed to PUD, and
it has long been suggested to be the most common cause of nonvariceal
UGIB12,13,14. Recent evidence suggests, however, that the incidence of
PUD as a cause of acute UGIB may either be decreasing or is
underreported. Widespread proton pump inhibitor prescribing and
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Helicobacter pylori eradication protocols also likely contribute to this
observed downward incidence trend of PUD causing nonvariceal UGIB.
Classically, Mallory-Weiss tears are mucosal lacerations at the
gastroesophageal junction or in the cardia of the stomach15. These lesions
can be associated with repeated retching or vomiting and are another
important cause of nonvariceal UGIB. It is estimated that 5% to 15% of
all cases of acute UGIB are secondary to Mallory-Weiss tears16,17,18. Most
bleeding episodes caused by Mallory-Weiss tears are self-limited and do
not require endoscopic hemostasis .Vascular ectasias, also referred to as
‘‘angiomas,’’ ‘‘arteriovenous malformations,’’and ‘‘angiodysplasia,’’ are
another source of acute and chronic nonvariceal UGIB19. Vascular
ectasias are the underlying etiology of acute UGIB in approximately 5%
to 10% of cases and the severity of bleeding can also range from trivial to
severe.
Isolated vascular ectasias are endoscopically different than the
diffuse linear array seen in gastric antral vascular ectasia, also referred to
as ‘‘watermelon stomach’’20,21. Gastric antral vascular ectasia(GAVE) is
thought to be a distinct clinical entity from portal hypertensive
gastropathy and is characterized by red stripes interposed by normal-
appearing mucosa generally noted in the gastric antrum22.
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Dieulafoy’s lesion is a rare etiology in acute UGIB. Their
histopathologic description is a ‘‘caliber-persistent artery’’ in the
submucosal tissue23. These lesions represent the etiology for nonvariceal
UGIB in less than 5% of all UGIB cases24,25. On endoscopy, a
Dieulafoy’s lesion is akin to a visible vessel protruding from an ulcer, yet
without an underlying ulcer. Neoplasms, both malignant and benign, are
another infrequent cause of nonvariceal UGIB and comprise less than 5%
of all UGIB cases26. Although neoplasms make up a small fraction of
overall bleeding episodes, UGIB can be a common presenting sign for a
neoplasm and should be part of the differential diagnosis27. The lesion can
be a primary malignancy, such as esophageal, gastric, or duodenal
adenocarcinoma; esophageal squamous cellcarcinoma; gastric or
duodenal lymphoma; or a gastrointestinal stromal cell tumor.
Aortoenteric fistula (aortic aneurysm repair)28, hemobilia29 and
haemosuccus pancreaticus30 are other rare causes of nonvariceal UGIB
which should also be considered in any differential diagnosis. Finally,
iatrogenic injuries secondary to endoscopic procedures, such as
percutaneous endoscopic gastrostomy tube placement, are also rare causes
of nonvariceal UGIB31. 10%, however, and these figures have not
dramatically changed.
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DIAGNOSIS
Clinical Presentation and Patient Triage
A thorough medical history and careful physical examination are
critical in the assessment of an individual presenting with gastrointestinal
bleeding. Details from the patient history can help mold the differential
diagnosis and stratify patient outcomes. A history of taking nonsteroidal
anti-inflammatory drugs, aspirin, antiplatelet agents, or anticoagulation
therapies, such as warfarin, are important pieces of information to
acquire during the history. A history of documented PUD with previous
UGIB, known H.pylori infection and compliance with proton pump
inhibitor therapy are also important issues to address. Furthermore, the
aforementioned relationship between advanced age, chronic renal
insufficiency, valvular heart disease and vascular ectasias should be
noted. Advanced patient age also increases the likelihood of a
gastrointestinal neoplasm as a possible etiology32,33.
Nasogastric tube aspiration can be an important component of the
evaluation of UGIB. Studies evaluating the usefulness of nasogastric tube
aspiration in predicting high-risk lesions, such as a peptic ulcer with
active bleeding or a visible vessel, have produced large variations in
sensitivity, specificity, and positive and negative predictive values. In
general, overtly bloody nasogastric tube aspirates are correlated with
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high-risk endoscopic lesions in the upper gastrointestinal tract 34,35,36
Clinicians often question the need for an nasogastric tube in the setting of
melena or hematemesis. Nasogastric tube placement does not serve a
purely diagnostic purpose, however, and can be useful for gastric lavage
and has the potential to minimize the aspiration risk from a blood-filled
stomach in preparation for endoscopy37. Specifically, gastric lavage has
been shown to improve visualization of the gastric fundus when
performed before endoscopy for acute UGIB38. To risk stratify individuals
presenting with acute UGIB better, risk scoring tools have been
developed to facilitate patient triage, predict risk of rebleeding and
mortality, evaluate need for ICU admission, and determine need for
urgent endoscopy39. These scoring tools have been almost exclusively
used in research studies, and are uncommonly applied in everyday clinical
practice40. Some risk scoring tools, such as the Blatchford Score, use
laboratory findings, patient vital signs at presentation, and other clinical
variables without the use of endoscopy41. The complete Rockall Score
identified significantly more low-risk patients with acute UGIB than
either the clinical Rockall Score or the Blatchford Score. Risk
stratification may be important because of the potential to minimize the
unnecessary use of hospital-based services, iatrogenic complications, and
worker absenteeism.
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Gastrointestinal Endoscopy
Endoscopy is the best tool for both the diagnosis and ultimately as
a therapeutic measure for patients with acute UGIB. Improvements in
endoscopic technology and operator skill have clearly reduced the need
for surgery and interventional radiology as diagnostic and therapeutic
procedures for UGIB. Patient positioning before and during the procedure
can assist with improving visibility during endoscopy42. Positioning the
patient with the bleeding point in the most superior position can help clear
the endoscopic field by allowing blood to flow away from the point of
bleeding. Reverse Trendelenburg positioning and rolling the patient from
the left lateral decubitus position to the right and back can also be used to
move clots and blood away from dependent areas in the stomach. The
choice of endoscope is also a critical aspect of making an accurate
diagnosis for nonvariceal UGIB. A large single-channel or double
channel therapeutic endoscope should be used in all cases of suspected
acute UGIB. This technique should be used both for the ability to suction
larger volumes of gastroduodenal contents and for the potential to provide
hemostasis therapy using a large-size (10F catheter) thermal probe or
mechanical clipping device.
Early endoscopy, generally defined as within 24 hours of
hospitalization has been shown to reduce resource use, decrease
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transfusion requirements, and shorten hospital stay43,44. There is
conflicting evidence whether or not performing endoscopy even earlier
(eg, in the emergency department) can further decrease resource use and
minimize health care costs. Lee and colleagues45 demonstrated a
significant decrease in hospital costs and duration of stay with endoscopic
triage performed in the emergency. The presence of blood in the stomach
on upper endoscopy is an important finding when assessing risk initially.
Table 2:
Prevalence and Outcomes of PUD using endoscopic stigmata46
Endoscopic
Characteristics
Forrest
Classifications
Prevalence
% (range)
Rebleeding
% (range)
Surgery %
(range)
Mortality
% (range)
Clean base III 42(19-52) 5(0-10)
0.5
(0-3)
2(0-3)
Pigmented flat
spot
IIC 20(0-42) 10(0-13) 6(0-10) 3(0-10)
Adherent clot IIB 17(0-49) 22(14-36) 10(5-12) 7(0-10)
NBVV IIA 17(4-35) 43(0-81) 34(0-56) 11(0-21)
Active bleed IA 18(4-26) 55(17-100) 35(20-69) 11(0-23)
Active bleeding (spurting or oozing) or nonbleeding visible vessels
seen on endoscopy have the highest potential for rebleeding with rates of
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approximately 55% and 43%, respectively. This knowledge can guide the
decision for discharge, hospital admission, or admission to an ICU.
Despite the importance of making an accurate diagnosis, evidence
suggests that there is frequent intraobserver variability on grading
endoscopic stigmata47,48. If there is clinical evidence of recurrent bleeding
after primary hemostasis has been achieved,
esophagogastroduodenoscopy should be repeated with a view toward
repeat hemostasis if needed49. In UGIB secondary to PUD, rebleeding
occurs in approximately 10% to 30% of patients who have high-risk
stigmata (active bleeding, nonbleeding visible vessel, adherent clot) at the
time of initial esophagogastroduodenoscopy and who receive endoscopic
hemostasis50. In addition, evidence from recent studies suggests that
performing a second-look endoscopy (regardless of any clinical evidence
of recurrent hemorrhage) in patients with high-risk ulcer stigmata at the
time of their initial esophagogastroduodenoscopy may decrease
rebleeding rates, need for surgery, and health care costs51,52. The
feasibility and importance of this in actual clinical practice, however, may
be dependent on the health care setting of the patient and provider.
Using ultrasound as an accessory modality for cases of UGIB is not
a new Concept53. Much of the literature surrounding the use of
endoscopic ultrasound for UGIB involves gastroesophageal varices and
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other clinical issues related to portal hypertension54,55,56. The literature on
endoscopic ultrasound in nonvariceal UGIB is growing, however, and
reports exist of this technique being used as an adjunctive diagnostic tool
in a variety of settings including peptic ulcer hemorrhage, Dieulafoy’s
lesion, and evaluating hemobilia57,58. A Doppler ultrasound probe can be
passed through the accessory channel of a therapeutic endoscope. A
persistent Doppler ultrasound signal after endoscopic hemostasis in PUD
has been associated with a higher rebleeding rate, and some authors
endorse evaluating for the presence of a Doppler signal before and after
hemostasis therapy in PUD so as to ensure better complete hemostasis59.
Additional Modalities
Angiography and technetium scanning are useful alternatives when
endoscopy has not yielded a definitive diagnosis or is unable to be
performed. Other radiographic studies may also be useful when making
the diagnosis of UGIB, but not usually in the acute setting. An
esophagram, or upper gastrointestinal series, and small bowel follow-
through were used more for the diagnosis of UGIB before the advances in
endoscopic technologies over the past two decades and generally are no
longer used as part of the diagnostic evaluation of persons with acute
UGIB60,61,62.
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Wireless capsule endoscopy is now being used as a diagnostic tool
for a variety of gastrointestinal disorders including Crohn’s disease, celiac
disease, and obscure gastrointestinal bleeding63,64. At the present time,
however, it is not a practical modality to use in acute UGIB.
TREATMENT
Nonvariceal upper gastrointestinal bleeding (UGIB) remains a
common emergency for gastroenterologists with an annual incidence of
50 to 150 per 100,000 of the population. Mortality from UGIB is around
10%, and may reach 35% in patients hospitalized with another medical
condition. Serious comorbidity remains an independent risk factor for
UGIB mortality, which is often attributable to increasing age and
associated illnesses. A recent time trend analysis by a Dutch group has
demonstrated a decrease in incidence of UGIB (from 61.7 per 100,000 per
year in 1993–1994 to 47 per 100,000 per year in 2000), but has not
demonstrated a reduction in mortality or rebleeding rates65, even though
there have been significant advances in medical and endoscopic
management of serious UGIB. An ageing population with potentially
serious comorbidities helps to explain the lack of concordance between
the overall population incidence and mortality rate for UGIB. Patients
over 80 years of age now account for around 25% of all UGIB and 33%
of UGIB occurring in hospitalized patients.
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ETIOLOGY OF NONVARICEAL UPPER GASTROINTESTINAL
BLEEDING
The causes and historically quoted frequencies of nonvariceal
UGIB are shown in Table 3.
Table 3:
Causes of nonvariceal upper gastrointestinal bleeding
Diagnosis Incidence (%)
Peptic ulcer 30-50
Mallory-Weiss tear 15-20
Erosive gastritis or duodenitis 10-15
Esophagitis 5-10
Malignancy 1-2
Angiodysplasia or vascular malformations 5
Other 5
There is controversy regarding the relative contribution of peptic
ulcer bleeding to overall UGIB rates. Recent data from the Clinical
Outcome Research Initiative suggest that the frequency of peptic ulcer as
a cause of UGIB may have been overestimated. In 7822 endoscopies
performed for UGIB, peptic ulcer was the likely cause in only 1610
patients (20.6%). Data from the Canadian Registry on Nonvariceal Upper
Gastrointestinal Bleeding and Endoscopy, however, identified peptic
ulcers in 50% of patients presenting to community and tertiary care
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Fig 1: Duodenal Ulcer
Fig 2: Gastric ulcer
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institutions between 1999 and 2002. Regardless of the historical
frequency of peptic ulcer bleeding, the incidence of peptic ulcer disease
should decline with more widespread Helicobacter pylori eradication. In
addition, widespread use of cyclooxygenase-2–specific nonsteroidal anti-
inflammatory drugs may also affect peptic ulcer risk, although
prescription of this particular class of drugs worldwide has been severely
affected by recent statements by the US Food and Drug Administration
and other national drug monitoring organizations.
CLINICAL RISK ASSESSMENT
One of the major challenges of managing UGIB involves
identifying patients who are at high risk of rebleeding and death;
conversely, identifying patients who are suitable for early discharge and
outpatient endoscopy is also important for effective resource use. Several
clinical scoring systems have been developed to help predict outcome for
patients with a view to improving patient management and promoting
cost-effective use of resources. In most published scoring systems, a
combination of clinical, laboratory, and endoscopic variables are
weighted to produce a score that predicts the risk of mortality, recurrent
hemorrhage, need for clinical intervention, or suitability for early
discharge. The most commonly used systems (Rockall score, the Baylor
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bleeding score, Blatchford score) were recently excellently reviewed by
Das and Wong66 . Several factors are associated with poor outcome from
UGIB and may be related to the patient’s presentation and comorbidities,
or to the behavior of the ulcer:
Shock
Melena
Anemia at presentation
Significant fresh blood in vomit, gastric aspirate, or rectum
Concurrent sepsis
General poor health
Liver, renal, cardiac disease
Large ulcer size
Persistent bleeding despite endoscopic therapy
Recurrent bleeding
Inclusion of endoscopic stigmata of recent hemorrhage (SRH) that relate
to increased risk of rebleeding and death into scoring systems increases
the sensitivity for predicting patients at high or low risk of adverse events
compared with nonendoscopic assessments67,68. In addition, early
endoscopy based triage may allow safe and early discharge of low-risk
patients with no increased rate of rebleeding or mortality. Risk
stratification using nonendoscopic parameters has the advantage that it
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can be performed readily on initial presentation in the emergency
department, however, and if early endoscopy, which requires skilled staff
and resources, is not available, appropriate initial risk assessment can be
made. Clearly, more studies are required to clarify the role of endoscopy
in early risk assessment. More generally, care must be taken when
applying a risk stratification scoring system to any patient population not
represented by the original studies, because racial, cultural, or ethnic
factors may affect a populations’ risk69.
INITIAL MANAGEMENT
Resuscitation and optimization of comorbid conditions are vital in
the initial management of patients before endoscopy. Transfusion of
blood and blood products may be necessary and patients often require
management in an intensive care setting. Endotracheal intubation remains
controversial in significant nonvariceal UGIB. The endoscopist’s task is
made easier and the risk of massive aspiration in a patient with reduced
level of consciousness is reduced if a patient is intubated; however,
evidence of a reduction in acquired pneumonia or cardiopulmonary events
is lacking . The presence of blood-stained nasogastric aspirate can be used
to predict the presence of high-risk lesions and nasogastric tube insertion
should be considered for some patients. The optimum timing of
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endoscopy remains a balance between clinical need and resources, but
endoscopy performed within 24 hours of hospital admission has been
shown to reduce the length of hospital stay and may reduce the likelihood
of rebleeding or surgical intervention in the highest risk patients70.
ENDOSCOPIC ASSESSMENT
Endoscopic SRH associated with a higher risk of rebleeding,
surgical intervention, and death have been well defined71. High-risk
lesions, such as actively bleeding ulcers, nonbleeding visible vessels
(NBVV), and adherent clots72 require aggressive intervention because
ulcer rebleeding is associated with a 5- to 16-fold increase in mortality ,
and effective endoscopic management can substantially reduce this risk.
The rebleeding rate of ulcers with a clean base or red or blue spots is low,
and endoscopic intervention is usually not recommended69. Although
actively bleeding vessels are consistently identified by endoscopists, this
is not the case for other SRH, particularly NBVV and flat pigmented
spots. Attention has turned to alternative approaches to assess lesions
more objectively. Doppler examination of ulcers was assessed as a means
of obtaining objective evidence of rebleeding risk in 100 patients
admitted with UGIB but not bleeding at the time of index endoscopy.
Doppler findings were compared with the Forrest classification of the
ulcer73. Ulcers were assessed for the presence of blood vessels and were
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considered to be Doppler-positive if a vessel no deeper than 1 mm was
identified. Doppler-positive ulcers and those in the Forrest group with
adherent clot or visible vessels were treated endoscopically. There was
agreement between the Forrest classification and Doppler in only 58% of
cases. Rebleeding, requirement for surgery, and mortality rate were all
significantly lower in the Doppler-assessed group. The authors suggest
that Doppler assessment can guide appropriate endoscopic intervention
for patients with NBVV. Technical and resource limitations, however,
mean this technique is unlikely to be widely available for some time. Not
infrequently, excessive blood in the upper gastrointestinal tract may
preclude an accurate endoscopic diagnosis. A retrospective study by
Cheng and coworkers identified 25 of (1.7%) 1459 patients where a
diagnosis could not be made endoscopically because of blood obscuring
the examination field. Not surprisingly, these patients had a significantly
higher rate of complications, rebleeding, need for surgery, and mortality.
The authors stress the importance of good preparation along with the
removal of blood during the procedure. Bolus administration of
intravenous erythromycin before endoscopy has been shown to clear the
stomach of blood, thereby increasing the likelihood of successful
hemostasis and reducing the need for further interventions74,75
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ENDOSCOPIC MANAGEMENT
Endoscopic intervention is beneficial in high-risk patients with
UGIB, reducing the rate of rebleeding, need for surgical intervention, and
mortality. It is likely that most hemostatic techniques are equally effective
when used alone. Recent research has focused on the role of combination
therapies and newer mechanical means of homeostasis76. Most of the
following text refers to peptic ulcer bleeding but may be applicable in
other causes of nonvariceal UGIB.
Injection Therapy
Injection of dilute (1:10,000) adrenaline in 1-mL aliquots around
the bleeding points results in hemostasis in up to 100% of patients with
bleeding peptic ulcers, probably by a combination of vascular tamponade
and vasoconstriction, with a concomitant reduction in rebleeding rates
from 40% to 15%77,78. The dose of adrenaline required to achieve
hemostasis is probably dependent on the individual patient; however, in a
study of 156 patients with Forrest type I or IIa lesions a larger volume
(13–20 versus 5–10 ml) resulted in less rebleeding (15.4% versus 30.8%)
Although injection with adrenaline is successful in achieving initial
hemostasis, the published rebleed rates of 15% to 36% remains relatively
high. Attention has focused on alternative techniques (eg, heat or
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mechanical) or combination therapy to determine if there is any additional
benefit. Sclerosants, such as ethanol, polidocanol, and ethanolamine, have
been used to promote vessel thrombosis, but evidence to date suggests
these agents are no better, and may have more risk, than adrenaline. In
one study, ethanol injection alone was shown to have a rebleeding rate as
low as 4% however, most other published studies have demonstrated
similar or worse rates of hemostasis than adrenaline alone. A combination
of adrenaline and ethanol may improve hemostasis and shorten duration
of hospital stay for patients with spurting hemorrhage79.
Thrombin-fibrinogen mixture (fibrin-sealant glue) does not seem to
confer any additional benefit beyond adrenaline alone when used in a
one-off basis in combination with adrenaline injection for patients with
high-risk peptic ulcers, although it may be of particular use in patients
with active bleeding. A study involving 51 patients with active bleeding
or NBVV demonstrated lower rebleeding rates with a single treatment
with combination adrenaline and fibrin sealant compared with adrenaline
alone, although there was no difference in mortality, transfusion
requirements, surgery, or duration of hospital stay. Repeated injection of
fibrin glue following treatment with dilute adrenaline in patients with
active bleeding or NBVV was subsequently compared with single
application of fibrin glue or polidocanol following adrenaline injection.
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Patients underwent daily endoscopy until the ulcer base was clean or
covered in hematin. Patients in the repeat treatment group had
significantly higher rates of hemostasis with less rebleeding compared
with the polidocanol group, although mortality rates were not reduced.
The major drawback of this schedule is the cost incurred by repeated
daily procedures.
In another study, endoscopic intervention with a combination of
adrenaline injection and 600 to 1000 IU human thrombin has been shown
to be more effective than injection of adrenaline alone, with a reduction in
rebleeding (4.5% versus 20%), transfusion requirement, and mortality80.
Injection with N-butyl-2-cyanoacrylate has been shown to be effective for
control of variceal bleeding, but its role in nonvariceal UGIB remains
uncertain. In a small study of 32 cases it was no more effective than
injection with dilute adrenaline for control of bleeding ulcers. More
recently, Lee and coworkers showed significantly lower rebleeding rate
for patients with Forrest type Ia lesions treated with N-butyl-2-
cyanoacrylate compared with injection with hypertonic saline-adrenaline
injection. There was no overall benefit in the use of N-butyl-2-
cyanoacrylate with regards to hemostasis rates, emergency surgery, or
mortality. Arterial embolization is a recognized complication of this
treatment, and occurred in 2 of 63 patients in the treatment group. The
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authors recommend N-butyl-2-cyanoacrylate injection only as a measure
of last resort before surgery because of potentially fatal adverse effects.
Thermal Techniques Several thermal techniques have been used for the
control of nonvariceal UGIB. Homeostasis is achieved by compression of
the artery during heating (coaption) and the effect of heat on tissue.
Noncontact thermal techniques
Laser (neodymium:yttrium-aluminum-garnet) and argon plasma
coagulation are the only noncontact thermal therapies currently available.
Argon plasma coagulation causes hemostasis by conducting a high-
frequency electricalcurrent through a beam of ionized argon gas, resulting
in superficial tissue damage and coagulation. Although the technique is
generally safe and relatively straightforward, the efficacy has yet to be
fully determined. A prospective observational study into the use of argon
plasma coagulation in 254 patients with nonvariceal UGIB revealed initial
hemostasis rates of 75.9% and rebleeding rates of 5.7% with argon
plasma coagulation alone. When a second endoscopic technique was
added, initial hemostasis was achieved in 99.6%. In the only comparative
randomized trial involving argon plasma coagulation in nonvariceal
UGIB, rates of hemostasis, rebleeding, emergency surgery, and 30-day
mortality were comparable with the heater probe, although the numbers in
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this study (N ¼ 41) were too small to detect a difference . Chau and
coworkers compared combination treatment with adrenaline and heater
probe with adrenaline and argon plasma coagulation in a prospective,
randomized, and controlled trial involving 185 patients with bleeding
peptic ulcers. There was no significant difference in primary hemostasis,
procedure duration, rebleeding, requirement for surgery, 30-day mortality,
or ulcer healing at 8 weeks, suggesting that combination therapy with
adrenaline and argon plasma coagulation is as effective as heater probe in
high-risk patients with bleeding ulcers. Laser therapy has been shown to
be as effective as injection with epinephrine- polidocanol , but because of
technical constraints of the technique, laser therapy is not routinely used
in the management of nonvariceal UGIB.
Contact thermal techniques
Bipolar electrocoagulation and heater probe thermocoagulation use
thermal contact to achieve hemostasis by compression of the vessel and
coaption. A bipolar electrocoagulation device may include an injector-
irrigator component (eg, Gold probe, Boston Scientific, Boston, MA) to
allow injection of adrenaline and irrigation of the culprit lesion. Bipolar
electrocoagulation has been shown to reduce the rebleeding rate when
compared with normal saline injection in high-risk bleeding ulcers, and in
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combination with adrenaline in type IIb ulcers. Combination therapy with
heater probe thermocoagulation and adrenaline in the treatment of
actively bleeding peptic ulcers resulted in hemostasis in up to 98.6%, with
rebleeding in 8.2%. In another study, however, there was no significant
difference in rates of rebleeding, requirement for surgery, and length of
hospital stay when compared with adrenaline alone. Subgroup analysis,
however, did illustrate benefit in patients with Forrest Ia lesions, with
dual therapy resulting in significantly lower rebleeding rates and non
significant reductions in emergency surgery and length of hospital stay.
When used alone, heater probe thermocoagulation was not superior to
combination treatment with adrenaline and polidocanol in patients with
Forrest type I, IIa, and IIb ulcers. Heater probe thermocoagulation (HPC)
in combination with thrombin was compared to HPC and placebo in 247
patients with bleeding peptic ulcers and was found to confer no benefit
when compared with the placebo arm with regards to hemostasis,
rebleeding rates, requirement for surgery, adverse events, or mortality
Mechanical Techniques Mechanical methods of achieving hemostasis are
often used in variceal UGIB.
Endoloops and particularly clips (eg, the Hemoclip [Teleflex
Medical, Research Triangle Park, NC]), however, are likely to play an
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increasing role in the control of nonvariceal UGIB. Hemostasis using
endoclips involves deployment of a clip to achieve vascular compression.
So far the Hemoclip has been safe and effective, achieving homeostasis
rates of up to 100%. Comparative studies with other endoscopic
techniques suggest lower rebleeding rates than adrenaline injection,
ethanol, or hypertonic saline-epinephrine. The additional benefit of
adrenaline with a mechanical method is unclear. A randomized
comparative study of injection of epinephrine-polidocanol and Hemoclip
versus Hemoclip alone, however, showed clipping to be inferior to
combination Hemoclip– adrenaline injection therapy in the treatment of
bleeding peptic ulcers81. Chung and coworkers found the Hemoclip to be
an effective method for hemostasis and safer than hypertonic saline-
epinephrine, and combination treatment with injection therapy and
Hemoclips was equivalent to either treatment alone for control of
bleeding. Rebleeding rates and the need for surgery were higher,
however, in the adrenaline group. A potential limitation of the Hemoclip
is the technical difficulty in applying the clips to difficult-to-reach lesions,
particularly those high on the gastric lesser curve or posterior wall of the
duodenum. This was demonstrated in a comparative study of Hemoclip
with heater probe thermocoagulation in which the overall rates of
hemostasis were 85% and 100%, respectively. In the subgroup of
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difficult-to-approach lesions the homeostasis rate fell to 30% and 82%,
respectively. Rotatable and more versatile endoclips may help to lessen
this problem. In addition, devices that can deploy multiple or stronger
clips are needed. Two small studies have evaluated the role of Hemoclips
for control of bleeding caused by Dieulafoy’s lesion. Hemostasis was
generally successful and there was a trend toward reduction in the need
for repeat procedures.
Endoscopic band ligation is currently technically easier to use than
endoclips and has been shown to be safe and effective for control of small
lesions in 19 patients with acute peptic ulcer bleeding. Rubber band
ligation has recently been assessed in a small group of patients with
UGIB secondary to Dieulafoy’s lesion and found to be as effective as
injection with or without thermal therapy.
Adherent Clots
Special mention needs to be made regarding the problem of
adherent clots. A subgroup analysis of patients with adherent clots in
early endoscopic studies demonstrated little or no benefit of endoscopic
therapy for ulcers with adherent clots. A subsequent meta-analysis
showed significant benefit only in patients with active bleeding or NBVV.
A randomized controlled trial to assess endoscopic intervention in
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patients with severe UGIB and adherent clot randomized 32 patients to
medical or combination therapy following irrigation of the clot.
Endoscopic therapy consisted of adrenaline injection shaving of the clot
with cold guillotine, and bipolar coagulation of the underlying stigmata.
Combination therapy was shown to be safe with significantly less early
rebleeding compared with medical therapy, although the small sample
size, unexpectedly low rebleed rates in the treatment group (0%), and
unequal distribution of confounding factors in the two groups means that
caution needs to be taken when extrapolating the results. In addition,
various studies have shown intraobserver variation in the labeling of
SRH, and the degree of clot adherence may vary depending on the extent
of clot irrigation. For instance, in one study 5 minutes of irrigation by a
bipolar probe was found to remove clot in 43% of patients, whereas
irrigation with a syringe only removed 9% of the clot. In another study,
10 seconds of irrigation with WaterPik (Teledyne, Fort Collins, CO)
removed clots in a further 26% of patients. Placement of a newly
designed transparent irrigating hood that allows forceful irrigation yet
maintains a reasonable endoscopic view may prove useful for clot
removal. Although the optimum technique for clot removal is unclear, the
value of clot removal is clear, because high-risk SRH may be exposed in
the underlying ulcer in a further 30% of patients. Rebleeding rates for
45
untreated ulcers with adherent clot are reported as 20% and in the group
where clots remained was 8%, which is similar to that expected in low-
risk lesions, such as flat pigmented spots. Current practice among
experienced endoscopists involves targeted irrigation of an adherent clot
to dislodge it, if possible, followed by treatment of the underlying lesion.
SECOND-LOOK ENDOSCOPY AND ENDOSCOPIC
RETREATMENT
Several studies investigating the role of routine second-look
endoscopy following endoscopic treatment have shown no benefit with
regards to clinically significant outcomes for unselected patient
populations, although there may be a role in high-risk patients. Repeat
endoscopy is indicated if there is clinical evidence of rebleeding or if the
initial procedure was unsuccessful or partially successful, although this
depends on local endoscopic and surgical expertise69,82. In expert centers,
endoscopic retreatment is associated with fewer complications, less need
for surgery, and no increased mortality risk compared with surgery.
FUTURE DIRECTIONS IN ENDOSCOPY
Endoscopic suturing a variety of endoscopic suturing devices have
been developed primarily for gastroplication in patients with
gastroesophageal reflux. Endoscopic suturing for UGIB is an attractive
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prospect, but further development of new devices is required before
suturing for UGIB can be widely adopted. Such issues as the device size
and maneuverability, and precise control of suture depth, need to be
addressed.
Cryotherapy
Cryosurgery involves freezing tissue to achieve a therapeutic
response. Gastric freezing to achieve hemostasis during variceal and
nonvariceal bleeding has been possible for several decades, although
evidence of therapeutic benefit from the original techniques was lacking.
More recently, delivery systems for liquid nitrogen or nitrous oxide have
made endoscopic cryotherapy possible for bleeding and other
applications. Delivery of nitrous oxide to result in cryotherapy relies on
the Joule-Thompson effect: rapid expansion of compressed gas results in
a drop in temperature of the gas. This allows noncontact therapy to
localized or diffuse vascular lesions. The technique remains experimental,
but it seem to be safe and effective for radiation proctitis and vascular
malformations, and there may be potential use in other gastrointestinal
vascular lesions.
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PROTON PUMP INHIBITORS
In vitro studies of the effect of gastric pH on platelet aggregation
and coagulation provide the rationale for acid suppression in UGIB. If
gastric pH is maintained above pH6 (by infusional proton pump
inhibitors), platelet aggregation is optimized and fibrinolysis relatively
inhibited, thereby potentially improving the likelihood of clot stability at
an ulcer site. Individual trials of H2 receptor antagonists have generally
failed to demonstrate a clinical benefit in UGIB , although a meta-
analysis has suggested a weak effect . Several studies have evaluated
intravenous proton pump inhibitors for nonvariceal UGIB; unfortunately,
these trials are heterogeneous in terms of patient population, regimen of
proton pump inhibitor, and timing or type of endoscopic intervention,
making comparisons difficult. Five meta-analyses of proton pump
inhibitors in nonvariceal UGIB have now shown a benefit, however, in
terms of rebleeding and need for surgery, but not for mortality83-87. The
usual intravenous regime for omeprazole therapy in the more robust
studies was an 80-mg intravenous bolus of omeprazole followed by a
continuous infusion of 8 mg/h for up to 72 hours. This regimen resulted in
a reduction of rebleeding from 22.5% to 6.7%, representing a number
needed to treat (NNT) of 6 to prevent one person bleeding within 30 days.
Subsequent studies using lower intravenous doses of omeprazole or
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high-dose oral omeprazole also demonstrated a reduction in rebleeding
rate. Further study is required to determine the optimum dose and
schedule of proton pump inhibitors in UGIB. It seems reasonable,
however, to treat patients with high-risk SRH with intravenous or high-
dose oral proton pump inhibitors after endoscopic therapy has been
administered.
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ALGORITHM FOR MANAGEMENT OF NONVARICEAL UGIB
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VARICEAL BLEED
Variceal bleeding is one of the dreaded complications of portal
hypertension. Although its prognosis has improved over the last several
decades, it still carries substantial mortality. Although most portal
hypertensive bleeds result from the ruptured distal esophageal varices,
bleeding from other sources such gastric varices, portal hypertensive
gastropathy, and ectopic varices can lead to clinically significant
bleeding. The following sections review management of acute variceal
bleeding, prevention of rebleeding, bleeding from gastric varices and
portal hypertensive gastropathy, and the prevention of first variceal
bleeding.
MANAGEMENT OF ACUTE VARICEAL BLEEDING
The following guidelines optimizes the management of acute variceal
bleed
1. Initial resuscitation
2. Early endoscopy
3. Endoscopic therapeutic procedures like Endoscopic variceal
banding or sclerotherapy. (EVL slightly better than EST).
4. Vasoconstrictors like Octreotide , Somatostation, Terlipressin88.
Studies have demonstrated the supremacy of Terlipressin over
others.
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FIG 3:    BLEEDING ESOPHAGEAL VARICES
FIG 4:   BLEEDING FUNDAL GASTRIC VARICES
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FIG 5: ENDOSCOPIC VARICEAL BANDING
FIG 6: FUNDAL GASTRIC VARIX WITH EVIDENCE OF RECENT bleed
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5. TIPS89 (Trans arterial Intra hepatic Portovenous Stent) used as
salvage for those patients who could not be treated by
endotherapy or who rebleeds.
6. Shunt surgeries should be reserved as the last resort for
refractory bleed
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Algorithm for managing acute variceal bleed
Yes
No
A Cirrhotic with Upper GI bleeding
Volume Resuscitation
Endoscopic Band Ligation (preferred) or Sclerotherapy
Begin Intravenous Antibiotics Somatostatin or Octreotide or Terlipressin
Upper Endoscopy
 Complete 3-5 day course of Octreotide
 Complete a 7 day course of Antibiotics
 Repeat endoscopic band ligation every
10-14 days to eradication
Consider Transjugular
Intrahepatic Portosystemic Shunt
(TIPS) or surgical shunt
Hemostasis Achieved
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PREVENTING RECURRENT VARICEAL BLEEDING
Without further therapy, once initial control is achieved, variceal
bleeding recurs in two thirds of patients within 2 months. Factors
associated with increased risk of recurrent bleeding include presence of
active bleeding on initial endoscopy, large varices, severity of initial
hemorrhage, decompensation, impaired renal function, presence of
encephalopathy, and severe portal hypertension (as measured by the
hepatic venous pressure gradient). Because of the high risk of recurrent
hemorrhage, secondary prophylaxis should be initiated shortly after an
episode of bleeding.
Pharmacologic Therapy
The main goal of pharmacologic is to significantly reduce portal
hypertension, ideally to reduce the hepatic venous pressure gradient
below12 mmHg, and to prevent recurrent bleeding. Therefore, the ideal
way to adjust medical therapy would be to follow portal pressure as
determined by the hepatic venous pressure gradient. The best time to
measure portal pressure would be within the first month after a bleeding
episode to determine which patients have severe portal hypertension and
have the greatest risk of recurrent bleeding. More than a 20% reduction in
portal pressure has been shown to significantly reduce the cumulative
probability of recurrent bleeding from 28% to 4% in the first year and
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from 39% to 9% at 2 years. Unfortunately, pressure measurements are
expensive, invasive, and not readily available. Therefore, surrogate
measures of portal pressure reduction commonly are used, such as a target
heart rate of 55 beats per minute or a 25% reduction in the heart rate from
baseline. Not all patients, however, are protected from bleeding. Recent
studies have shown that despite adequate beta-blocker therapy, there are a
percentage of patients that still have hepatic venous pressure gradients
above 12 mmHg, which puts them at continued risk for variceal
hemorrhage90.
Several trials have demonstrated the efficacy of a nonselective
beta-blocker compared with placebo in decreasing the risk of recurrent
bleeding and improving survival. The addition of isorbide mononitrate
(ISMN) to a betablocker regimen appears to further reduce the rate of
rebleeding. In addition, recent studies have shown that combination
pharmacologic therapy may be superior to sclerotherapy and band
ligation. Incidence of rebleeding was 25% over an 18-month period with
combination medical therapy compared with 53% for sclerotherapy in
Child-Pugh class A or B cirrhotics these same investigators compared
combination therapy with band ligation and demonstrated a reduction in
bleeding frequency from 49% to 33%. The benefit of combined medical
therapy, however, was realized mainly in patients who had Child-Pugh
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class A or B cirrhosis. More recent studies comparing combination
pharmacologic therapy with band ligation revealed conflicting results. Lo
and colleagues observed that band ligation was superior to combination
medical therapy. A study by Patch and colleagues observed that both
treatment modalities were equivalent. Most likely the differences in
results lie in study methods. Combination therapy may be superior to
endoscopic therapy. The adverse effects of pharmacologic therapy,
especially with combination pharmacologic medical therapy, however,
can limit compliance.
Endoscopic therapy
Even though sclerotherapy has been shown to be effective in
reducing recurrent variceal hemorrhage and appears to be equivalent to
beta-blocker therapy, band ligation appears to have similar efficacy in
decreasing recurrent bleeding, but fewer complications and higher
survival rates91. Therefore, for endoscopic therapy to prevent rebleeding,
band ligation should be considered the procedure of choice. Combination
band ligation with pharmacologic therapy may be the ideal treatment
modality. So far, there have been two published trials comparing band
ligation alone with band ligation plus pharmacologic therapy. In a study
by Lo and colleagues comparing band ligation alone with band ligation
plus nadolol and sucralfate, rebleeding was reduced from 47% to 23%
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with combination therapy. A more recent study by Pena and colleagues
comparing band ligation alone with band ligation plus nadolol,
demonstrated that the rebleeding rate was reduced from 38% to 14% with
the combination group. In addition, postbanding ulcers are common, and
significant bleeding from these ulcers occurs in 2% to 5% of cases.
Varices rebleeding rates potentially can be reduced further by adding
antiulcer therapy after endoscopic therapy. Shaheen and colleagues
performed a study to evaluate the efficacy of proton pump inhibitor in
treating postbanding ulcers in the setting of elective endoscopic band
ligation. This was a randomized double-blinded, placebo-controlled trial.
After elective endoscopic band ligation, subjects received either
intravenous pantoprazole 40 mg followed by 40 mg oral pantoprazole
daily for 9 days (n ¼ 22) or intravenous/oral placebo (n ¼ 22). There was
no difference in the number of postbanding ulcers among the groups.
Ulcers in the control group, however, were twice as large as the
pantoprazole group (82 mm2 versus 37 mm2, P < .01). Two patients had
postbanding ulcer bleeding; both were in the control group (P > .05).
Because proton pump inhibitors are tolerated well and simple to
administer, their use in this setting appears reasonable.
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Surgical Shunt and Transjugular Intrahepatic Portosystemic Shunt
Portocaval or distal splenorenal shunts have been used in
preventing recurrent variceal bleeding. A meta-analysis comparing distal
splenorenal shunt with sclerotherapy found that shunt placement
significantly reduced the rate of recurrent bleeding but also increased the
incidence of encephalopathy and did not improve survival. Rebleeding
after surgical shunts typically is caused by shunt thrombosis, which
occurs usually within the first year. It is unusual for surgical shunts to
thrombose beyond 1 year. Similarly, with TIPS compared with
endoscopic therapy the rebleeding rate was significantly lower with TIPS,
19% versus 47%, but the incidence of encephalopathy was higher with
TIPS, 34% versus 19%, with no difference in survival. Rosemurgy and
colleagues compared TIPS with a surgically place H-graft shunt. This was
a nonrandomized study of 132 patients. Rosemurgy and colleagues
observed that the frequency of rebleeding was significantly less in the
surgical group (3% versus 16%), and the patients who had TIPS required
frequent interventions to maintain shunt patency. Thirty-day mortality
rates, however, were higher in the surgical group, 43% versus 15%.
Therefore, surgical shunts should be used to prevent rebleeding in patients
who do not tolerate or are not compliant with medical therapy and have
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relatively preserved liver function. TIPS should be reserved for patients
who have poor liver function and who have failed medical therapy.
BLEEDING FROM PORTAL HYPERTENSIVE GASTROPATHY
Portal hypertensive gastropathy (PHG) is the characteristic mosaic-
like gastric mucosa with or without red spots; it is seen quite frequently in
patients with both cirrhotic as well as noncirrhotic portal hypertension.
Although the bleeding from PHG can be acute or chronic in nature,
chronic bleeding presenting as iron deficiency anemia or occult blood in
stool is far more frequent than acute bleeding. The specific treatment
options for significant PHG include nonselective beta-blockers,
endoscopic therapy, or TIPS or surgical shunts92. Nonselective beta-
blockers have been shown to reduce the risk of bleeding in patients who
have PHG. Endoscopic therapy in the form of cauterization (heater or
bipolar probe or argon plasma coagulation) or injection sclerotherapy can
be effective in patients who have acute bleeding caused by PHG. With
argon plasma coagulation, especially if such endoscopic expertise is
available locally. TIPS can reduce the bleeding from severe PHG
effectively.
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BLEEDING FROM GASTRIC VARICES
Gastric varices are rare but important sources for bleeding in
patients who have portal hypertension. Gastric varices can be classified
into gastro–esophagealvarices (GOV) or isolated gastric varices (IGV).
GOV are classified further into GOV 1 (in continuity with esophageal
varices and extend 2 to 5 cm below the gastroesophageal junction) or
GOV 2 (esophageal varices extending into the fundus). IGV can be
located in the fundus (IGV 1) or body/antrum (IGV 2). Gastric varices
located in the gastric fundus (either GOV 2 or IGV 1) carry a greater risk
of bleeding than those located in other parts of the stomach.
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Potential treatments for gastric variceal bleeding include
endoscopic (cyanoacrylate93 or its derivatives or thrombin), radiological
(TIPS or balloon-occluded retrograde transvenous obliteration)94, and
surgical (gastric devascularization and splenectomy, surgical shunts, or
liver transplantation) modalities.
63
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Materials and Methods
This study was done at Coimbatore Medical College Hospital,
Coimbatore from March 2009 to November 2010 after getting approval
by the Ethical committee.
Study Design:
Prospective Study
Inclusion Criteria:
100 patients admitted in medical, surgical and specialty
departments of Coimbatore Medical College Hospital with history of
Upper Gastrointestinal Bleed and in whom UGI scopy was performed
were included in this study.
Exclusion Criteria:
 Children less than 12 years of age
 Pregnant women
 Hemodynamically unstable patients
 Patients with coagulopathies, epistaxis, or gum bleed
All patients were informed prior to the procedure about nature of
procedure and a well informed consent was obtained.
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Study Methodology:
A complete history was taken from all enrolled patients which
included
1. No of episodes of  hematemesis
2. Approximate quantity of bleed (total)
3. Presence of melena
4. History of previous Upper Gastrointestinal Bleed or treatment
for Upper Gastrointestinal Bleed
5. History of intake of NSAIDs including aspirin and steroids
6. History of alcohol intake and smoking
7. History of prior surgery, organ transplantation
A thorough clinical general and systemic examination was done. The
following factors were assessed
1. General condition and vital signs
2. Assessment of severity of blood loss (BP, Postural Hypotension,
Tachycardia )
3. Assessing signs of portal hypertension (ascites, splenomegaly
and jaundice)
4. Presence of hepatic encephalopathy
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Laboratory tests:
The following lab investigations were done.
1. Hemoglobin, Total Count, Differential Count
2. Packed Cell Volume
3. Blood Urea and Serum Creatinine
4. Blood grouping and Rh typing
5. Coagulation profile
6. Liver function test (Serum bilirubin, SGOT, SGPT,
Alkaline phosphatase, Serum proteins)
Upper Gastrointestinal Endoscopy:
Upper Gastrointestinal endoscopy was done in the Department of
Gastroenterology, Coimbatore Medical College Hospital using Pentex
EG291C endoscope after eight hours of fasting to directly visualize the
mucosa of the esophagus, stomach and duodenum.
The endoscopic stigmata of active or recent hemorrhage and
endoscopic prognostic features like number of ulcers, site and location of
ulcers, size of ulcers, bleeding or not healing or not, clean base of the
ulcer or adherent blood clot, oozing of blood from the ulcer base and
visible blood vessel were studied. The site, grading of varices were
studied and search for rare causes for UGI bleed were made.
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Endoscopic interventions like injection therapy, Endoscopic
sclerotherapy, EVL were done as needed.
All patients were treated with resuscitative measures, transfusions,
vasoconstrictors, PPI, H2RI and antibiotics as needed.
All data were tabulated.
Statistical Analysis :
Done with Chi-square with ANNOVA
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OBSERVATIONS AND RESULTS
Upper gastrointestinal bleed is a common medical emergency.
Coimbatore medical college hospital is a tertiary care institution which
caters to three districts and treats sizeable number of patients with upper
gastrointestinal bleed. 100 cases that presented with UGI bleed and
underwent UGI scopy were evaluated for the study.
Sex Distribution:
In this study of 100 cases of UGI Bleed the sex distribution is
observed as
Table 5.1 :
Gender Distribution
Sex No. of Cases Total No. ofCases Percentage (%)
Male 71 100 71%
Female 29 100 29%
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Figure: 5.1
Males were predominantly affected with UGI bleed (71%).
Age Distribution:
In this study of 100 cases of upper Gastrointestinal bleed the age
distribution observed is as follows
Table 5.2
Age wise Distribution
Age in years No. of Cases Total No. of Cases Percentage (%)
< 20 7 100 7%
20-40 32 100 32%
40-60 41 100 41%
>60 20 100 20%
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Figure 5.2:
Predominant age group is 40-60 years, accounting for 41 %.
Hemoglobin:
We assorted the patients admitted with upper gastrointestinal bleed
into two groups based upon the hemoglobin values in grams/dl.
The results are given below.
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Table 5.3
Hemoglobin at Initial Presentation
Hb (grams /dl) No. of cases Total No. of cases No. of Deaths
<8 34 100 9
> 8 66 100 0
Vital Parameters:
Pulse, blood pressure and conscious level play an important role in
prognostication. The results are as follows
Table 5.4. Vitals
Parameter Grade
No. of
Patients
Total No. of
cases
Pulse
<100 82 100
>100 18 100
Blood
pressure
< 100 29 100
>100 71 100
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ICU Stay
Of the 100 cases in whom endoscopy was done 30 patients were
admitted in Intensive Care Unit and there were 9 deaths in total. All
deaths occurred in patients admitted in ICU.
Fig. 5.3.
Tachycardia, Hypotension, ICU stay and Encephalopathy are high
risk features.
History:
 Out of 100 patients, 48 (48%) patients were alcoholics
 57 (57%) patients were found to be smokers
 History of NSAID  intake was observed in 17 (17%) cases.
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 Previous history of UGI bleed was present in 11 (11%)
cases.
Comorbidities
Comorbidities are major determinants of adverse outcomes  in UGI
bleed according to several studies, but in our study comorbidities did not
affect the outcome significantly probably due to lesser number of elderly
patients and lower incidence of comorbid illness in our study.
In our study, 17 patients had ascites, 3 had hepatic encephalopathy,
17 patients had hypertension and CAD and renal failure was noted in 5
cases.
Endoscopic Findings:
In this study in Upper Gastrointestinal Bleed the frequency of
clinical presentations observed are as follows
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Table 5.5.
Endoscopic Findings in 100 cases of UGIB.
Nature of lesion No. of cases Percentage (%)
Duodenal Ulcer 25 25%
Gastric Ulcer 4 4%
Esophageal Varices Gr-I 2 2%
Esophageal Varices Gr-II 5 5%
Esophageal Varices Gr-III 13 13%
Esophageal Varices +
Fundal Varices
3 3%
Gastric erosions 28 28%
Duodenitis 3 3%
Mallory Weiss 12 12%
Esophageal Ulcer 1 1%
Esophagitis 3 3%
Gastric Malignancy 4 4%
Peptic ulcer was the most common cause of upper gastrointestinal
bleed, with gastric erosion (28 %) being the most frequent lesion. It was
found that duodenal ulcer was the second most common lesion contributing
25% of UGIB. Variceal bleeding was noted in 20% of the patients.
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Table 5.6.
FORREST GRADING OF PEPTIC ULCER BLEED
Table -5.7.
VARICEAL FINDINGS
Lesion No of patients
Grade
Mild 2
Moderate 5
Severe 13
Column
Mild 2
Moderate 5
Severe 13
Gastric varices Present 3
PHT Gastropathy Present 6
Red Colour signs Present 11
High grade varices, red colour lesions, bluish varices are high risk
features for rebleed and mortality. 13 patients had high grade varices.
Lesion No of Cases
Active bleeding 7
NBVV 2
Adherent clot 10
Clean base or pigmented ulcer 19
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Blood Transfusions:
Out of 100 patients, 31 patients required blood transfusion and out
of them 4(4%) patients required more than 2 units of transfusions. Blood
transfusion was not required in 69(69%) of cases
Fig 5.4.
Blood Transfusion Requirement
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Discussion
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DISCUSSION
After enumerating the etiologies of UGIB, peptic ulcer constitutes
the most common cause, out of which duodenal ulcer constitutes 25%,
gastric erosions 28%, gastric ulcer 4%, duodenitis3% and esophageal
ulcer 1%.
This data correlates well with the UK registry of UGIB (Audit
committee) which was published in BMJ by Rockall TA et al. The
Canadian registry also has similar observations.
Malignancy accounted for 4%  of cases and varices constituted
20% of non ulcer bleed.
UGI scopy was the diagnostic modality of choice and done in all
cases. 74% of UGI scopy were done within 24 hours. Endoscopic
intervention were done as appropriate  and sclerotherapy was the most
preferred procedure than EVL for esophageal varices. This choice was
based on local preference, expertise and simplicity. Adrenaline injection
was the preferred endotherapy for ulcer bleed.
Compared data on the choice, EVL is the most common procedure
worldwide and widely accepted for esophageal variceal bleed. Head to
head trials comparing EST and EVL showed superiority of EVL over
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EST but visibility of the endoscopist after a torrential bleed is of concern
during EVL (Laine L, Cook D et al). Total number of death is 9 (9%).
We have formulated diagnostic criteria for major bleed as follows:
1. Death of the patient
2. Who had transfusion requirement of more than 2 units
3. Who had ICU stay more than 1 day
4. Hospital stay more than 3 days.
We have chosen a few patient parameters as potential risk factors for
early prediction of major UGIB. The parameters considered are age, BP,
HR, Hb at presentation,creatinine level, timing of endoscopy, endoscopic
diagnosis and endotherapy.
Using statistical analysis the following were observed :
Age was considered as an important predictor of death. Age > 60 is
associated with increased mortality (p<0.001). Age is not a predictor of
increased ICU stay (P < 0.102), increased transfusion requirement
(P<0.0305) or hospital stay (p<0.02).
This is compared with Rockall et al which has similar mortality in
> 60 years age group. Mortality increased with advancement of age
(Blatchford et al)
Blood pressure at presentation is found to have important predictor
of death and major bleed. BP < 100/70 is associated with increased death
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(P <0.001), increased hospital stay (P < 0.001) and increased transfusion
requirement (P<0.001).
Similar way cold peripheries (Shock) at presentation predicts
mortality, increased ICU stay, hospital stay and transfusion requirement
(P<0.001).
Study of Longstreth GF 1997 indicated that outcome of patient who
presented with shock had higher mortality and constituted about 17 % of
all bleeds.
Heart rate >100 correlated well with mortality (P<0.001), ICU stay
(P<0.001) and hospital stay (P<0.001).
Hb < 8gms/dl predicted the need for increased transfusion
(P<0.001), ICU stay (P=0), hospital stay (P=0) and death (P=0)
Creatinine >2mg/dl correlated well with death, ICU stay,
transfusion and hospital stay (P =0)
Presence of coronary artery disease is surprisingly neither a
predictor factor of mortality (P<0.171), ICU stay (P<0.954), transfusion
(P<0.799) nor hospital stay (P<0.481)
Presence of comorbidities like HT, CRF, arthritis, alcoholism or
smoking did not predict death of major bleed. This is in contrast to study
by Rockall which predicted high mortality for patients with comorbid
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illness. The discrepancy occurred because of skewed patients population
towards younger age and low incidence of comorbid illness in our study.
Timing of endoscopy and its possible improved outcome is a major
controversy in management of UGIB.
Various studies have produced variable results. In general UGI
scopy performed <24hrs did not have any added advantage in reducing
mortality or morbidity (Splejel BM et al ).
Optimal timing of UGI scopy is put variably by different authors.
But the consensus statement put it at < 24 hrs (Stering committee
Rockall et al).
Our series had 95 % of UGI done within 24 hrs. 78 % of patients
who died had UGI done <24 hrs. 22 % had UGI done after 24hrs
probably due to continued hemodynamic instability and resuscitation. The
mortality in these subgroup is statistically significant to early UGI scopy
group (P<0.004).
The timing of UGI correlated well with ICU stay and hospital stay has
expected. Patient who underwent endoscopy < 24hrs had good recovery
despite major bleed (P<0.004)
Endoscopic diagnosis of etiology emerged as the strongest
predictor of mortality. Diagnosis of esophageal varices, bleeding peptic
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ulcer contributed 98 % of all mortality signifying the importance
(P < 0.001).
Endotherapy  with sclerosant, adrenalin conveyed mixed results
when correlated with mortality. Patient needing endotherapy were very
sick contributing to overall mortality (P<0.001) but 69 % (16/23) of
patient were salvaged by endoscopy (P<0.001).
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CONCLUSION
1. 30% of the patients with UGIB had high mortality and morbidity.
(Major UGIB)
2. Strong predictors of major UGIB are Age>60, HR>100,
BP<100/70, Hb < 8gms/dl, Creatinine>2mgs/dl and shock at
presentation.
3. Endoscopy is the most valuable investigation for diagnosis. UGI
scopy done < 24 hrs predicted well with improved outcome.
4. Endoscopic diagnosis like esophageal varices, bleeding peptic ulcer
carried high mortality.
5. Endoscopic therapy (injection for ulcer bleed, sclerotherapy  for
varices) salvaged 69 % of major bleed and improved prognosis.
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INFORMED CONSENT
Department of General Medicine
Coimbatore Medical College, Coimbatore
Principal Investigator: Dr Anand Kumar
Research Guide: Dr. M. Raveendran
Organization: Department of General Medicine
Informed consent
I have been invited to participate in the research project titled
“Clinical Vs Endoscopic Correlation of Upper Gastro Intestinal Bleeding”
I understand it will involve answering a set of questionare, undergo
physical examination and to undergo Upper GI endoscopy.
I am aware of the procedure of endoscopy which may be associated
with discomfort and carries very minimal risk of adverse complications. I
am also aware that it may necessitate interventions through endoscope as
the case may warrant.
Also I give consent to utilize my personal details for study purpose
and can be contacted if necessary.
I am aware that I have the right to withdraw at any time which will
not affect my medical care.
Name of the participant:
Signature:
Date:
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PROFORMA
Study No :
Name: Age: Sex:
IP No: ward:
Address : Contact No:
History:
UGI bleed Hematemesis Melena Both
Date No of Times
Approx qty of Bleed
Prior Hospitalizations Details
Blood Transfusion
H/O Alcohol Details
H/O NSAIDs Details
H/O Smoking Details
H/O Aspirin Details
K/c of Liver disease PUD Others
DM SHT IHD CKD Others
Surgery in the past
Jaundice in the past Details
Previous endoscopy
After admission:
HR BP SpO2
No of blood transfusion required
Ryles tube aspirate Clear Blood
Basic investigations
Hb PCV Platelets Urae Creatinine
ECG CXR USG
Endoscopy
Performed after  within 24hrs > 24 hrs
Findings at endoscopy
Site of bleed
Nature of the bleed
Forrest grading for PUD bleed
Paquet grade of Variceal bleed
Intervention done
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LIST OF ABBREVIATIONS
 UGIB - Upper Gastro Intestinal Bleeding
 NSAID - Non Steroidal Anti-Inflammatory Drugs
 H.pylori - Helicobacter Pylori
 NVUGIB - Non Variceal Upper Gastro Instestinal Bleeding
 HVPG - Hepatic Venous Pressure Gradient
 CTP - Child Turcotte Pugh
 EVL - Endo Variceal Ligation
 EST - Endoscopic Sclero Therapy
 SRH - Stigmata of Recent Hemorrhage
 NBVV - Non Bleeding Visible Vessel
 HPC - Heater Probe thermo Coagulation
 TIPS - Transjugular Intrahepatic Porto Systemic shunt
 PHG - Portal Hypertensive Gastropathy
 GOV - Gastro-esophageal Varices
 IGV - Isolated Gastric Varices
 PPI - Proton Pump Inhibitor.
 ITU – Intensive Therapy Unit
 HPU – High Dependency Unit.
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1 Subramani 262 35 M N Y Duodenal ulcer 100/70 N 88 12 40 O.8 N N N N N N N 36 2 >24hrs no N
2 Kandasamy 275 66 M N Y Duodenal ulcer 70/50 Y 106 6.3 60 3.1 >1 2 N Y Y N Y 21 2 <24hrs adrenaline N
3 Ragavan 283 27 M N Y Gastric erosions 110/70 N 76 14 36 0.8 N N N N N N N 42 2 >24hrs no N
4 Rangasamy 284 65 M N Y Grade III Oesophageal varices + fundal varices 70/40 Y 112 4.6 54 2.5 >1 >2 Y N N N N 15 3 <24hrs Sclero N
5 Dhara 297 17 F N Y Duodenal ulcer 80/60 Y 118 6 52 2.3 >1 2 N N N N N 18 2 <24hrs adrenaline N
6 Jothi 311 30 F N Y Duodenal ulcer 80/62 Y 110 5.6 46 1.7 >1 2 N N N N N 18 2 <24hrs adrenaline N
7 Madhi Antony 318 48 M N Y Grade III Oesophageal Varices 80/60 Y 108 4.2 58 2.9 >1 2 N N N N N 16 4 <24hrs sclero N
8 Saraswathi 320 45 F Y N Gastric ulcer 120/80 N 78 10.4 36 0.7 N N N N N N Y 33 2 >24hrs no N
9 Suganya 324 18 F N Y Mallory - Weiss tear 110/80 N 88 10.8 32 0.8 N N N N N N N 33 2 >24hrs no N
10 Lakshmi 343 42 F N Y Duodenal ulcer 68/46 Y 106 4.8 60 3.1 >1 2 N N N N Y 16 2 <24hrs adrenaline N
11 Selvi 361 25 F N Y Mallory - Weiss tear 114/76 N 84 10.6 28 0.7 N N N N N N N 33 2 >24hrs no N
12 Parvathy 368 85 F N Y gastric erosions 80/60 Y 118 6.8 64 3.5 >1 2 Y Y Y Y Y 21 3 <24hrs no N
13 Veerasamy 369 61 M Y N gastric erosions 120/74 N 88 11 26 0.6 N N N N N N N 33 2 >24hrs no N
14 Agnes 383 13 F Y N gastric erosions 110/76 N 98 12 26 0.8 N N N N N N N 36 3 >24hrs no N
15 Babu 384 45 M N Y Grade II Oesophageal Varices 80/60 Y 120 6.2 52 2.3 >1 2 N N N N N 18 3 <24hrs Sclero N
16 Moorthy 385 42 M N Y Grade III Oesophgeal varices Narrowed Pylorus 80/60 Y 116 4.1 59 3 >1 2 N N N N N 16 4 <24hrs Sclero N
17 Murugesan 388 36 M Y N gastric erosions 110/80 N 88 13.2 28 0.6 N N N N N N N 39 2 >24hrs no N
18 Murugan 394 33 M N Y Mallory - Weiss tear 114/80 N 80 13.5 32 0.6 N N N N N N N 39 2 >24hrs no N
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19 Natraj 404 50 M Y N gastric erosions 120/78 N 78 13.6 36 0.8 N N N Y Y N Y 34 2 >24hrs no N
20 Shajagan 405 25 M N Y gastric erosions 110/70 N 76 13.4 32 0.9 N N N N N N N 40 2 >24hrs no N
21 Darmaraj 407 38 M N Y Duodenal ulcer 100/70 N 86 12.6 30 1 N N N N N N N 36 2 >24hrs no N
22 Kalamani 413 22 F N Y gastric erosions 112/80 N 84 10.6 27 0.8 N N N N N N N 30 3 >24hrs no Y
23 Senthil Kumar 416 41 M N Y gastric erosions 120/78 N 82 12 31 0.8 N N N N N N N 36 2 >24hrs no N
24 Selva Raj 427 28 M N Y Duodenal ulcer 110/78 N 76 12.6 36 0.9 N N N N N N N 39 2 >24hrs no N
25 Karupusamy 454 19 M Y N Duodenal ulcer 130/80 N 90 13 30 0.7 N N N N N N N 42 2 >24hrs no N
26 Selvakumar 455 27 M N Y Esophagitis 110/78 N 94 12.4 24 0.7 N N N N N N N 35 2 >24hrs no N
27 Iqbal 457 47 M N Y Duodenal ulcer 70/40 Y 114 4.7 64 3.5 >1 2 Y Y Y N Y 15 2 <24hrs adrenaline N
28 Mahalingam 460 62 M N Y gastric erosions 112/80 N 78 12 32 1.1 N N N Y Y N Y 36 3 >24hrs no N
29 Vasanthan 462 40 M N Y grade III Oesophageal varices 80/60 Y 102 4 57 2.8 >1 2 N N N N N 14 3 <24hrs Sclero N
30 Kanagaraj 466 20 M N Y Mallory - Weiss tear 112/76 N 84 12.4 27 0.8 N N N N N N N 36 4 >24hrs no N
31 Kumarasamy 469 38 M N Y grade III Oesophageal varices 80/60 Y 120 3.9 55 2.6 >1 2 N N N N N 14 4 <24hrs Sclero N
32 Kannan 474 38 M Y N gastric erosions 120/78 N 82 12.6 24 0.8 N N N N N N N 36 2 >24hrs no N
33 Laxmanan 479 48 M N Y Grade I Oesophageal varices 80/60 Y 118 6.7 61 3.2 >1 2 N Y Y N Y 21 3 <24hrs no N
34 Arusamy 487 70 M N Y gastric ulcer 110/70 N 78 12.6 32 0.7 N N N N N N Y 38 2 >24hrs no N
35 Revathi 489 16 F N Y Duodenal ulcer 100/70 N 80 11.2 23 0.8 N N N N N N N 33 1 >24hrs no N
36 Baskar 492 25 M N Y Duodenal ulcer 106/76 N 98 12.6 37 0.8 N N N N N N N 38 2 >24hrs no N
37 Ravi 496 42 M N Y gastric erosions 110/76 N 78 12.8 38 0.7 N N N N N N N 39 2 >24hrs no N
38 Jagadeesh 498 45 M N Y grade III Oesophageal varices + Fundal Varices 70/40 Y 116 5.5 63 3.4 >1 2 Y N N N N 18 3 >24hrs sclero N
39 ponnan 500 50 M N Y Scarred Oesophageal varices 80/60 Y 114 6.7 54 2.5 >1 2 N N N N N 21 3 <24hrs no N
40 Loganathan 505 45 M N Y Duodenal ulcer 110/74 N 84 11.6 40 1.2 N N N N N N N 35 2 >24hrs no N
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41 Arokyaraj 507 61 M N Y Duodenal ulcer 100/70 N 88 13.2 28 0.8 N N N Y Y N Y 39 2 >24hrs no N
42 Radha Mani 512 40 F N Y Duodenal ulcer 70/56 Y 124 4.6 53 2.4 >1 2 N N N N Y 15 1 <24hrs adrenaline N
43 Sitarasan 519 44 M N Y Grade II Oesophageal varices 80/60 Y 112 5.6 50 1.6 >1 2 N N N N Y 18 4 >24hrs evl N
44 Ajith Kumar 520 13 M N Y Mallory - Weiss tear 114/74 N 94 13.6 22 0.7 N N N N N N N 45 2 >24hrs no N
45 Nagaraj 532 73 M Y N Gastric malignancy 106/78 N 98 7.5 40 3 N N N N N N N 24 4 >24hrs no N
46 Palanisamy 536 50 M N Y Grade III/IV Columns Oesophageal varices 70/40 Y 110 6.9 68 3.7 >1 2 Y N Y N N 21 4 <24hrs sclero N
47 Mahadevan 538 57 M N Y grade III Oesophageal varices + fundal varices 70/40 Y 108 4.3 61 3.2 >1 >2 Y N Y N N 15 4 <24hrs sclero N
48 Arumugam 539 35 M N Y Grade III Oesophageal varices with 3 Columns 80/60 Y 106 3.8 50 2.1 >1 2 N N N N N 14 3 <24hrs evl N
49 Hariharan 540 38 M Y N Duodenitis 120/78 N 90 13.6 34 0.9 N N N N N N N 45 1 >24hrs no N
50 Poovathal 547 45 F N Y gastric erosions 118/78 N 88 10.4 26 0.8 N N N Y Y N N 33 3 >24hrs no N
51 Tulasiammal 555 50 F N Y Duodenal ulcer 70/40 Y 116 3.9 59 3 >1 >2 Y Y Y N Y 14 2 <24hrs adrenaline N
52 Valliammal 563 42 F N Y Duodenal ulcer 110/76 N 82 7.5 34 0.6 N N N N N N N 24 2 >24hrs no N
53 Muthu 574 36 M Y N gastric erosions 120/80 N 78 12.6 26 0.8 N N N Y Y N N 38 2 >24hrs no N
54 Masananan 575 48 M N Y gastric ulcer 124/82 N 74 12.6 36 0.9 N N N N N N N 38 2 >24hrs no N
55 Devasagayam 579 45 M N Y Grade l esophageal varices 80/60 Y 112 6.3 55 2.6 >1 2 N N Y N Y 21 5 <24hrs no N
56 Palanal 587 37 F N Y Esophagitis 110/76 N 76 10.4 32 0.9 N N N N N N N 34 2 >24hrs no N
57 Rageswari 590 30 F N Y Mallory - Weiss tear 126/78 N 80 10.6 28 0.9 N N N N N N N 30 4 >24hrs no N
58 Ravi 593 45 M N Y Mallory - Weiss tear 114/74 N 88 9.8 28 0.9 N N N N N N N 28 5 >24hrs no N
59 Abdul Kutty 591 50 M N Y gastric erosions 110/70 N 94 12.6 28 0.7 N N N Y Y N N 36 2 >24hrs no N
60 Srinivasan 597 60 M N Y Grade II oesophageal varices 80/60 Y 120 5.8 56 2.7 >1 2 N N Y Y Y 36 4 <24hrs Sclero N
61 Renganathan 601 46 M N Y GradeI oesophageal varices 80/60 Y 108 5.2 50 1.9 >1 2 N N N N N 18 3 <24hrs no N
62 Pechimuthu 602 32 M N Y Duodenal ulcer 116/78 N 84 13.2 28 0.8 N N N N N N N 15 1 >24hrs no N
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63 Kaleeswari 2 43 F N Y Mallory - Weiss tear 120/78 N 78 10.2 28 0.7 N N N N N N N 39 6 >24hrs no N
64 Sivagami 18 60 F N Y Gastric malignancy 80/60 Y 104 6.1 42 1.4 >1 2 N N N N N 30 6 <24hrs no N
65 Elangovan 37 27 M N Y gastric erosions 120/76 N 82 10.4 23 0.6 N N N N N N N 18 3 >24hrs no N
66 Shanthamani 41 44 F Y N Duodenal ulcer 126/78 N 88 12.4 26 0.8 N N N N N N N 30 2 >24hrs no N
67 Vasanthi 43 32 F Y N Duodenitis 110/70 N 94 10.4 32 0.8 N N N N N N N 36 1 >24hrs no N
68 Susammal 48 55 F N Y Grade lll oesophagial varices 100/70 N 98 6.8 48 1.7 >1 >2 Y N N N Y 30 4 <24hrs Sclero N
69 Selvi 50 30 F Y N gastric erosions 124/76 N 90 10.2 26 0.8 N N N N N N N 21 3 >24hrs no N
70 Subramani 78 43 M N Y gastric erosions 120/80 N 86 11.4 33 0.7 N N N N N N N 30 3 >24hrs no N
71 Chinna Durai 80 22 F N Y Duodenal ulcer 110/70 N 90 10.4 26 0.9 N N N N N N N 33 2 >24hrs no N
72 Shanmugam 82 60 M Y N gastric erosions 130/80 N 84 10 26 0.8 N N N Y Y Y N 30 2 >24hrs no N
73 Arumugam 83 45 M N Y Grade lll oesophagial varices 80/60 Y 116 3.7 50 2.1 >1 2 N N N N N 30 4 <24hrs Sclero N
74 Chinna Mani 110 70 M N Y Grade lll oesophagial varices 80/60 Y 112 5.2 60 3.1 >1 2 N N N N N 14 4 <24hrs Sclero N
75 Karuthammal 112 70 F N Y gastric erosions 110/70 N 82 10.6 36 0.8 N 1 N Y Y N Y 15 3 >24hrs no N
76 Subramani 113 73 M N Y gastric erosions 124/76 N 86 12.2 34 0.9 N N N Y Y N Y 33 2 >24hrs no N
77 Rajesh 121 40 M N Y gastric erosions 110/70 N 90 13.2 32 0.8 N N N N N N N 36 3 >24hrs no N
78 Murugathal 126 40 F N Y Duodenal ulcer 100/70 N 94 10.4 27 0.7 N N N N N N N 39 2 >24hrs no N
79 Sankar 131 30 M Y N gastric erosions 124/82 N 78 12.4 29 0.8 N N N N N N N 30 2 >24hrs no N
80 Kalamani 140 30 F Y N Duodenitis 106/76 N 74 10.6 32 0.9 N N N N N N N 36 1 >24hrs no N
81 Raju 161 82 M N Y gastric ulcer 108/76 N 98 13.4 28 0.7 N N N N N N Y 39 3 >24hrs no N
82 Thulasimani 178 39 F N Y Duodenal ulcer 120/80 N 90 10.4 35 0.9 N N N N N N N 30 2 >24hrs no N
83 Beer Mohammed 182 61 M N Y Mallory - Weiss tear 110/76 N 84 12.6 38 0.9 N N N N N N N 37 2 >24hrs no N
84 Rajendran 184 28 M N Y Duodenal ulcer 106/76 N 78 13.6 28 0.7 N N N N N N N 39 2 >24hrs no N
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85 Guru Moorthy 191 45 M N Y gastric erosions 124/82 N 90 13.8 88 4.6 N N N Y Y N N 41 2 >24hrs no N
86 Palanisamy 199 41 M N Y Duodenal ulcer 110/70 N 96 12.4 36 0.8 N N N N N N N 38 1 >24hrs no N
87 Murugesan 204 69 M Y N Gastric malignancy 102/74 N 92 7.5 27 0.8 N N N N N N N 23 5 >24hrs no N
88 Ganapathy 206 75 M N Y gastric erosions 110/78 N 88 12.8 34 0.8 N N N Y Y Y Y 38 3 >24hrs no N
89 Thangammal 211 55 F N Y gastric erosions 104/74 N 82 10.6 36 0.9 N N N Y Y N Y 33 2 >24hrs no N
90 Selvam 216 45 M N Y Mallory - Weiss tear 120/82 N 78 12 26 0.7 N N N N N N N 36 2 >24hrs no N
91 Kuppuraj 217 55 M N Y Esophagitis 110/72 N 72 12.4 28 0.8 N N N N N N N 37 3 >24hrs no N
92 Nanda Kumar 218 26 M N Y Duodenal ulcer 108/78 N 70 13.6 32 0.8 N N N N N N N 39 2 >24hrs no N
93 Rahuman 225 42 M Y N gastric erosions 120/78 N 74 12.4 34 0.9 N N N N N N N 37 3 >24hrs no N
94 Madurai Veeran 230 45 M N Y Mallory - Weiss tear 116/78 N 76 12.6 28 0.7 N N N N N N N 38 3 >24hrs no N
95 Selvam 240 45 M N Y Esophageal ulcer 114/80 N 80 13.6 30 0.8 N N N N N N N 41 2 >24hrs no N
96 Mohammed Ali 243 52 M N Y Mallory - Weiss tear 100/70 N 82 13.6 28 0.7 N N N N N N N 42 3 >24hrs no N
97 Lakshmi 244 38 F N Y Duodenal ulcer 106/76 N 88 7.5 25 0.7 N N N N N N N 22 2 >24hrs no N
98 Krishna Samy 253 60 M N Y Grade lll oesophagial varices 80/60 Y 110 5.1 58 2.9 >1 2 N N N N N 16 2 <24hrs sclero N
99 Palanisamy 254 73 M N Y Gastric malignancy 70/40 Y 104 4.5 98 4.8 >1 2 Y N Y Y N 14 6 >24hrs no N
100 Ram Kumar 255 27 M N Y gastric erosions 116/74 N 82 13.4 34 0.8 N N N N N N N 39 2 >24hrs no N
